Los Angeles, July 2, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces the mutual release of Sobriety and Addiction Solutions, LLC (SAS) from its license agreements with the Company. They were previously offering the Start Fresh Program for locations in Walnut Creek, Fresno and Washington D.C. under MyLife Recovery Centers (MyLife). With different views on how to best approach and capture market share of the $35 billion addiction treatment industry, the companies felt that this separation would allow each party to pursue their respective strategies to help more people suffering from addiction in the largely fragmented addiction treatment market.
BioCorRx, Inc. will continue to pursue its distribution goals for the Start Fresh Program as expressed in press releases earlier this year, while MyLife and SAS will pursue their own expansion plans using a different program. The companies will further create and validate the market for this treatment methodology, which both companies believe is the future of addiction treatment. Together or separately, the companies plan to advocate for wider acceptance from the medical community, government entities, and payors.
"Together our companies created more awareness about how effective addiction treatment can be when therapy is combined with medication in a long lasting, implantable form. I feel that our separation will create better products and more awareness for this sector, which should ultimately be better for both companies, but more importantly for families struggling with addiction," said Brady Granier, COO & interim CEO of BioCorRx.
Visit BioCorRx, Inc.'s investor relations website at www.BICXcorp.com to receive the most up to date company information.
About BioCorRx, Inc.
BioCorRx, Inc. ® (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program®, a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program. For more information on BICX, visit www.BioCorRx.com
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
CONTACT: Investor Relations SmallCapVoice.com, Inc. 512-267-2430